Comparing diabetes prediction based on metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease

The Elsa-Brasil study

Bibliographic Data

ID5167394
AuthorsGabriela Wünsch Lopes (0000-0002-6862-0914, Universidade Federal do Rio Grande do Sul), Scheine Leite Canhada (0000-0002-4324-9848, Universidade Federal do Rio Grande do Sul), Rodrigo Citton Padilha Dos Reis (0000-0003-1766-0964, Universidade Federal do Rio Grande do Sul), Maria De Fátima Haueisen Sander Diniz (0000-0001-9146-5003, Universidade Federal de Minas Gerais), Ana Caroline Goulart (0000-0003-1076-5210, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brasil; Universidade de São Paulo, Brazil), Luciana Costa Faria (0000-0002-0226-3491, Universidade Federal de Minas Gerais), Rosane Harter Griep (0000-0002-6250-2036, Fundação Oswaldo Cruz), Hugo Perazzo (0000-0003-0931-6418, Fundação Oswaldo Cruz), Bruce B Duncan (0000-0002-7491-2630, Universidade Federal do Rio Grande do Sul), Maria Ines Schmidt (0000-0002-3837-0731, Universidade Federal do Rio Grande do Sul)
Year2024
Volume40
Issue11
Pagese00009924-e00009924
Publication date2024-01-01
Open AccessYes
TypeARTICLE
VenueCadernos de Saude Publica (JOURNAL)
Journal identifiersISSN: 0102-311X • E-ISSN: 1678-4464
PublisherFapUNIFESP (SciELO) (PUBLISHER)
DOI10.1590/0102-311xen009924
PMID39607105
OpenAlexW4404698035
SciELOS0102-311X2024001101402
LanguageEN
References cited37

We aimed to compare nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) definitions concerning diabetes prediction in a large sample of Brazilian adults. As a secondary objective, we compared associations between NAFLD/MASLD and diabetes across self-declared race/skin color groups. The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) is a prospective cohort study of Brazilian civil servants (35-74 years) enrolled from 2008 to 2010 and followed up from 2012-2014 and 2017-2019. We ascertained type 2 diabetes mellitus at baseline as well as follow-up visits based on self-reported diagnosis, medication use, and glycemic tests (fasting and 2h post-OGTT glucose and HbA1c). We excluded individuals with heavy alcohol consumption or self-reported cirrhosis/hepatitis. We analyzed 7,073 subjects. NAFLD was defined by ultrasound-based steatosis. Participants with steatosis and at least one cardiometabolic factor were considered as having MASLD. Cox proportional hazards models were performed to evaluate the association between NAFLD/MASLD and the incidence of type 2 diabetes mellitus. At baseline, 33.9% of individuals presented NAFLD and 32.5% presented MASLD. Over 9.4 years of follow-up, the relative increase in the incidence of diabetes was 78% for NAFLD (HR = 1.78; 95%CI: 1.58-2.01) and 88% for MASLD (HR = 1.88; 95%CI: 1.67-2.12). Associations did not differ significantly among race/skin color groups (p for interaction = 0.10 for MASLD and 0.08 for NAFLD). In this large cohort of middle-aged and older Brazilian adults, the relative incidence of diabetes was similar for NAFLD and MASLD definitions, with similar associations in all ethnic groups

Diabetes mellitus · Disease · Fatty liver · Liver disease · Nonalcoholic fatty liver disease · Diabetes, Cardiovascular Risks, and Lipoproteins · Diet, Metabolism, and Disease · Endocrinology · Gastroenterology · Internal Medicine · Liver Disease Diagnosis and Treatment · Medicine

Tools

Open DOIOpen Access